Mast cell tumors are the most common cutaneous tumors in dogsWithrow, S.J. and Vail, D.M. Small Animal Clinical Oncology, Elsevier Inc, Canada 402-421, 2007.Welle MM, et al. Veterinary Dermatology 2008;19:321–339.McNeil EA, et al. Veterinary and Comparative Oncology 2006;4:2–28.Murphy S, et al. Veterinary Record. 2006;158(9):287–291.
Mast Cell Tumors (MCTs) are a cancer of mast cells. Mast cells arise in the bone marrow, travelling to sites to mediate an inflammatory response by releasing granules of histamine and heparin. It is not known exactly why mast cells form MCTs, but it happens often enough for this to be the most common form of cutaneous cancer in dogs.
Factors that can make surgery less suitable:
STELFONTA® (tigilanol tiglate injection) is a prescription treatment approved by the FDA and indicated for:
Tumors must be less than or equal to 10 cm3 in volume, and must be accessible to intratumoral injection.
IMPORTANT SAFETY INFORMATION
Accidental self-injection of STELFONTA® may cause severe wound formation. To decrease the risk of accidental self-injection, sedation of the dog may be necessary. In dogs, do not inject STELFONTA into subcutaneous mast cell tumors located above the elbow or hock. Formation of wounds, possibly extensive, is an intended and likely response to treatment with STELFONTA along with associated swelling, bruising and pain; these wounds are expected to heal. Appropriate pre- and post-treatment medications must be given, including a corticosteroid plus blocking agents for both H1 and H2 receptors, in order to decrease the potential for severe systemic adverse reactions, including death, from mast cell degranulation. For full prescribing information, contact VIRBAC at 1-800-338-3659 or view the Product Insert.